1025687-58-4
Chemical Structure
Fostamatinib Disodium
Synonym(s): R788Disodium
- CAS No.: 1025687-58-4
- Formula:C23H24FN6Na2O9P
- Molecular Weight:624.42
IUPAC Name: sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate
InChIKey: HSYBQXDGYCYSGA-UHFFFAOYSA-L
SMILES: COC1=CC(NC2=NC=C(C(NC3=NC(N4COP(O[Na])(O[Na])=O)=C(C=C3)OC(C)(C)C4=O)=N2)F)=CC(OC)=C1OC
Biological Activity: Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406[1]. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM[2]. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fostamatinib Disodium | 98.30% | Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fostamatinib Disodium (Standard) | ≥98% | Fostamatinib Disodium (Standard) is the analytical standard of Fostamatinib Disodium. This product is intended for research and analytical applications. Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Stephen P McAdoo, et al. Fostamatinib Disodium. Drugs Future. 2011;36(4):273. [Content Brief]
- [2]. Sylvia Braselmann, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. [Content Brief]
- [3]. Hoon-Suk Cha , et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317(2):571-8. [Content Brief]
